KR100292124B1 - 온단세트론을포함하는경구조성물 - Google Patents

온단세트론을포함하는경구조성물 Download PDF

Info

Publication number
KR100292124B1
KR100292124B1 KR1019970703400A KR19970703400A KR100292124B1 KR 100292124 B1 KR100292124 B1 KR 100292124B1 KR 1019970703400 A KR1019970703400 A KR 1019970703400A KR 19970703400 A KR19970703400 A KR 19970703400A KR 100292124 B1 KR100292124 B1 KR 100292124B1
Authority
KR
South Korea
Prior art keywords
composition
ondansetron
sorbitol
range
sweetener
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019970703400A
Other languages
English (en)
Korean (ko)
Other versions
KR970706815A (ko
Inventor
레누 갬버
Original Assignee
그레이햄 브레레턴
글락소 웰컴 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100292124(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그레이햄 브레레턴, 글락소 웰컴 인크. filed Critical 그레이햄 브레레턴
Publication of KR970706815A publication Critical patent/KR970706815A/ko
Application granted granted Critical
Publication of KR100292124B1 publication Critical patent/KR100292124B1/ko
Assigned to 글락소스미스클라인 인크 reassignment 글락소스미스클라인 인크 권리의 전부이전등록 Assignors: 글락소 웰컴 인크.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019970703400A 1994-11-22 1995-11-20 온단세트론을포함하는경구조성물 Expired - Lifetime KR100292124B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423588.4 1994-11-22
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions
PCT/IB1995/001152 WO1996015786A2 (en) 1994-11-22 1995-11-20 Oral compositions containing ondansetron

Publications (2)

Publication Number Publication Date
KR970706815A KR970706815A (ko) 1997-12-01
KR100292124B1 true KR100292124B1 (ko) 2001-07-12

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703400A Expired - Lifetime KR100292124B1 (ko) 1994-11-22 1995-11-20 온단세트론을포함하는경구조성물

Country Status (32)

Country Link
US (1) US5854270A (enExample)
EP (1) EP0792149B1 (enExample)
JP (1) JP2965704B2 (enExample)
KR (1) KR100292124B1 (enExample)
CN (1) CN1108153C (enExample)
AT (1) ATE196084T1 (enExample)
AU (1) AU703932B2 (enExample)
BE (1) BE1009458A5 (enExample)
BR (1) BR9509807A (enExample)
CA (1) CA2205546C (enExample)
CY (1) CY2171B1 (enExample)
CZ (1) CZ285187B6 (enExample)
DE (1) DE69518767T2 (enExample)
DK (1) DK0792149T3 (enExample)
ES (1) ES2151083T3 (enExample)
FI (1) FI119356B (enExample)
FR (1) FR2727015B1 (enExample)
GB (2) GB9423588D0 (enExample)
GR (1) GR3034684T3 (enExample)
HU (1) HU226947B1 (enExample)
IE (1) IE950884A1 (enExample)
IL (1) IL116083A (enExample)
IT (1) IT1282353B1 (enExample)
NO (1) NO306892B1 (enExample)
NZ (1) NZ297879A (enExample)
PL (1) PL181522B1 (enExample)
PT (1) PT792149E (enExample)
RU (1) RU2145853C1 (enExample)
SI (1) SI0792149T1 (enExample)
TW (1) TW413634B (enExample)
WO (1) WO1996015786A2 (enExample)
ZA (1) ZA959820B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
WO2001013909A2 (en) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
SK6182003A3 (en) * 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
ATE364611T1 (de) * 2002-04-29 2007-07-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur herstellung von 1,2,3,9-tetrahydro- 9-methyl-3- (2-methyl-1h-imidazol-1-yl)methylö- h-carbazol-4-on
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2478099B1 (en) 2009-09-18 2019-06-05 Chase Pharmaceuticals Corporation Combination for treating alzheimer-type dementia
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH22672A (en) * 1984-01-25 1988-11-14 Glaxo Group Ltd Imidazolylmethyltetrahydrocarbazolone derivatives, composition and method of use thereof
EP0385517B1 (en) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Medicaments for the treatment of emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharm. Res. 1994 Jan;11(1):156-9의 1부 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Also Published As

Publication number Publication date
FI119356B (fi) 2008-10-31
CN1108153C (zh) 2003-05-14
AU4313596A (en) 1996-06-17
NO972324D0 (no) 1997-05-21
US5854270A (en) 1998-12-29
HK1009590A1 (en) 1999-06-04
KR970706815A (ko) 1997-12-01
CY2171B1 (en) 2002-08-23
NZ297879A (en) 1998-12-23
BE1009458A5 (fr) 1997-04-01
DE69518767T2 (de) 2001-05-31
EP0792149A2 (en) 1997-09-03
FI972168L (fi) 1997-05-21
RU2145853C1 (ru) 2000-02-27
NO972324L (no) 1997-07-21
SI0792149T1 (en) 2001-02-28
CZ154897A3 (en) 1997-10-15
NO306892B1 (no) 2000-01-10
IL116083A0 (en) 1996-01-31
CA2205546A1 (en) 1996-05-30
MX9703734A (es) 1997-09-30
CZ285187B6 (cs) 1999-06-16
HU226947B1 (en) 2010-03-29
WO1996015786A3 (en) 1996-06-27
ZA959820B (en) 1996-07-29
DK0792149T3 (da) 2000-12-18
IL116083A (en) 2000-09-28
FI972168A0 (fi) 1997-05-21
BR9509807A (pt) 1997-10-21
GB9423588D0 (en) 1995-01-11
PT792149E (pt) 2001-02-28
DE69518767D1 (de) 2000-10-12
JPH10508866A (ja) 1998-09-02
FR2727015B1 (fr) 1997-08-22
GB9523666D0 (en) 1996-01-24
IE950884A1 (en) 1996-05-29
GB2295317B (en) 1998-11-25
GR3034684T3 (en) 2001-01-31
GB2295317A (en) 1996-05-29
CA2205546C (en) 2000-01-25
TW413634B (en) 2000-12-01
IT1282353B1 (it) 1998-03-20
ITRM950763A0 (enExample) 1995-11-20
WO1996015786A2 (en) 1996-05-30
CN1171740A (zh) 1998-01-28
EP0792149B1 (en) 2000-09-06
HUT77944A (hu) 1998-12-28
ITRM950763A1 (it) 1997-05-20
PL181522B1 (en) 2001-08-31
AU703932B2 (en) 1999-04-01
ES2151083T3 (es) 2000-12-16
ATE196084T1 (de) 2000-09-15
PL320288A1 (en) 1997-09-15
FR2727015A1 (fr) 1996-05-24
JP2965704B2 (ja) 1999-10-18

Similar Documents

Publication Publication Date Title
US5854270A (en) Oral compositions containing ondansetron
EP0793495B1 (en) Freeze-dried ondansetron compositions
US8263652B2 (en) Stabilized pediatric suspension of carisbamate
US12491179B2 (en) Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
HU225051B1 (en) Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
WO2022115681A2 (en) Methods and compositions for oral pilocarpine liquid
MXPA97003734A (en) Oral compositions containing ondanset
KR101058749B1 (ko) 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
US6265449B1 (en) Aqueous compositions comprising ranitidine and LCMT sucrose
CA2205600C (en) Freeze-dried ondansetron compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970521

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19971106

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990827

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000421

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20010126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20040113

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050114

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060113

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070112

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080117

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090121

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20100122

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20110225

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20120228

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20140227

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20150227

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term